MIA TRUPIANO: Open Payments
NPI 1053697599 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$670 in 32 payments from 10 companies in 2025. Trend: 2023 $97 · 2024 $309 · 2025 $670
Food & beverage: $670
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $318 |
| E.R. Squibb & Sons, L.L.C. | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $60 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Indivior Inc. | 1 | $36 |
| Braeburn Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Exact Sciences Corporation | 1 | $20 |
Products named: CAPLYTA, COBENFY, REXULTI, FANAPT, SUBLOCADE, BRIXADI, AUSTEDO XR, INGREZZA.
Industry payments across LA — which companies pay providers there.
